The company boasts a Return on Equity (ROE) of 42.1 per cent, coupled with an impressive profit growth of 71.9 per cent Compound Annual Growth Rate (CAGR) over the last five years.

hese grants are earmarked for endeavors in the realm of Tuberculosis (TB) and Human Papillomavirus (HPV) tests on the innovative Co-DX PCR Home platform. The intention behind these grants is to enable the completion of these vital tests, geared toward vital global markets, where the prevalence of these conditions is pronounced.

The company's net profit also experienced an extraordinary leap, rocketing up by an impressive 228 per cent to reach Rs 2.46 crore. While these exceptional earnings figures may already leave you astounded, the real astonishment lies in an even more remarkable revelation – its extraordinary order book.